|
Full Length
Research Paper
|
|
A meta
analysis of the efficacy and safety of moxifloxacin in
Chinese patients with multi-drug resistant pulmonary
tuberculosisosis
Shaoxia Liu1,
Shanshan Chen 1, Xinwei Ren2 and
Guojun Zhang1*
1Department
of Respiratory Medicine, First Affiliated Hospital of
Zhengzhou University, Zhengzhou, Henan, 450052, China.
2Department
of Pharmacy, Second Affiliated Hospital of Zhengzhou
University, Zhengzhou, Henan, 450014, China.
*Corresponding author. E-mail:
zhang450052@sina.com.
Accepted 13 December, 2011 |
|
|
|
Abstract |
|
|
This study was performed to evaluate the
efficacy and safety of moxifloxacin in treating
Chinese patients with multi-drug resistant
pulmonary tuberculosisosis (MDR-TB). Medicinal
databases and review articles were screened with
pre-specified criteria for randomized controlled
trials that reported the effects of and adverse
reactions to moxifloxacin and other
antituberculosisosis drugs in treating Chinese
patients with MDR-TB. The quality of included
studies was critically evaluated. A total of 948
articles were found and 12 articles finally
included. Heterogeneity test: Sputum negative
conversion analysis (Q statistic = 9.43, p
= 0.58, I2 = 0%), change of pulmonary
tuberculosisosis cavity analysis (Q statistic =
2.93, p = 0.89, I2 = 0%),
focus absorption analysis (Q statistic = 20.13,
p = 0.03, I2 = 50%) and safety
analysis (Q statistic = 10.98, p = 0.44,
I2 = 0%). The results of
meta-analysis showed that compared with the
control group, moxifloxacin was more effective
in sputum negative conversion (OR = 3.34, 95%
CI: 2.37 to 4.70) and focus absorption (OR =
2.53, 95% CI: 1.55 to 4.12). Moreover,
moxifloxacin was safer than control group (OR =
0.73, 95% CI: 0.55 to 0.96). Funnel-plot
displayed some unsymmetrical figures, indicating
there were publication biases in each analysis.
The evidence currently available shows that the
moxifloxacin treatment on Chinese patients with
MDR-TB is useful for the sputum negative
conversion and focus absorption.
Key words:
Moxifloxacin, pulmonary tuberculosisosis, systemic review,
meta-analysis.
|
